MétaCan
Menu
← Back to cohort
Record W4293240917 · doi:10.21203/rs.3.rs-1587568/v1

Safety and efficacy of allogeneic hematopoietic stem cell transplantation in R/R B-NHL patients with disease progression after CAR-T therapy

2022· preprint· en· W4293240917 on OpenAlexfundno aff
Mengya Cong, Sicheng Ai, Liqing Kang, Mao Jin, Ying Zhu, Caixia Li, Zhengming Jin, Lei Yu, Depei Wu, Haiwen Huang

Bibliographic record

VenueResearch Square · 2022
Typepreprint
Languageen
FieldMedicine
TopicCAR-T cell therapy research
Canadian institutionsnot available
FundersYork University
KeywordsMedicineLymphomaInternal medicineHematopoietic stem cell transplantationTransplantationGastroenterologyRegimenLymphoblastic lymphomaChemotherapySurgeryOncologyT cellImmunology

Abstract

fetched live from OpenAlex

Abstract Background: R/R B-NHL patients with disease progression after CAR-T therapy have poor prognosis and no standard chemotherapy regimen has been defined. We aimed to explore whether receiving allo-HSCT could improve the outcomes of R/R B-NHL patients who have disease progression after CAR-T therapy.Methods: From October 2017 to June 2021, we retrospectively report outcomes of R/R B-NHL patients with disease progression after CAR-T cell treatment, then receiving allo-HSCT. Results: Among 9 patients, 4 were males and 5 females, with a median age of 44 (27-52) years. 5 patients were diagnosed refractory/relapsed diffuse large B cell lymphoma, 1 patient was Burkitt lymphoma, 1 was B lymphoblastic lymphoma, 1 was transformed DLBCL and 1 was gray zone lymphoma. 8/9 donors were haploidentical family member, 1/9 donor was identical sibling. The median time from CAR-T treatment to transplantation was 2.3 (1.0-12.3) months. 9/9 patients obtained complete engraftment. The median time of neutrophil implantation was 12 (11- 19) days, and 13 (9-20) days of platelet implantation. The median follow-up was 7.9 (3.4-48.6) months. 4/9 patients received CR and 1/9 patient received PR during the follow up. The objective response rate (ORR) was 55.6%. The six-months overall survivaln (OS) and progression-free survival (PFS) were 66.7% and 33.3%, respectively. 1 case experienced acute graft-versus-host disease(aGVHD)grade Ⅱ, 1 case with aGVHD grade Ⅲ. Among 5 survivals, localized chronic GVHD occurred in 1 patient. During the follow up, four patients have died and the causes were disease relapses and progressions (2 patients), acute renal failure (1 patient), severe pulmonary infection (1 patient). No-relapse mortality was 22.2%.Conclusion: The present study demonstrated that allo- HSCT is a feasible and safe choice with favorable outcome for R/R B-NHL patients with disease progression after CAR-T therapy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.029
GPT teacher head0.360
Teacher spread0.331 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueResearch Square→Same topicCAR-T cell therapy research→French-language works237,207→